



Synlogic to Present at Jefferies 2017 Global Healthcare Conference

June 2, 2017

CAMBRIDGE, Mass. –([BUSINESS WIRE](#))–Synlogic announced today that its President and Chief Executive Officer, Jose Carlos Gutierrez-Ramos, Ph.D., will speak at the Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 1:30 p.m. in New York City. Synlogic is advancing a novel new class of living medicines using the company's proprietary discovery and development platform. The company's Synthetic Biotic™ medicines are designed to perform critical functions or deliver therapeutic factors to compensate for what is missing or damaged due to disease. Synthetic Biotic medicines have the potential to be deployed against a wide array of diseases – from rare metabolic disorders to inflammatory bowel disease to cancer.

About Synthetic Biotic™ Medicines:

Synlogic's innovative new class of Synthetic Biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer beneficial, probiotic microbes to perform critical functions or deliver therapeutic factors to compensate for what is missing or damaged due to disease. The company's two lead programs target a group of rare metabolic diseases – inborn errors of metabolism (IEM). Patients with these diseases are born with a faulty gene, inhibiting the body's ability to breakdown commonly occurring by-products of digestion that then accumulate to toxic levels and cause serious health consequences. When delivered orally, these medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect. Synthetic Biotic medicines are designed to clear toxic metabolites associated with specific metabolic diseases and promise to significantly improve the quality of life for affected patients.

About Synlogic™

Synlogic™ is pioneering the development of a novel class of living treatments, Synthetic Biotic™ medicines, based on its proprietary drug discovery and development platform. Synlogic's initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit synlogictx.com.

Forward Looking Statements:

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases, including IBD, and the continued preclinical development of Synthetic Biotic-based treatments pursuant to the AbbVie collaboration. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, the uncertainties inherent in the preclinical development process, the ability of Synlogic to protect its intellectual property rights and legislative, regulatory, political and economic developments.

Contacts

Synlogic

MEDIA CONTACT:

Courtney Heath, 617-872-2462

courtney@scientpr.com

or

INVESTOR CONTACT:

Christina Tartaglia, 212-362-1200

christina@sternir.com